Boston Scientific Corporation (NYSE: BSX) today announced the completion of a public offering of $2 billion aggregate principal amount of its senior notes under the Company’s shelf registration statement. The public offering consists of $850 million of 4.50 percent notes due January 2015, $850 million of 6.00 percent notes due January 2020 and $300 million of 7.375 percent notes due January 2040. Boston Scientific plans to use the net proceeds for general corporate purposes, including prepaying its bank term loan due April 2011.
Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering was made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint bookrunners: Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, 3rd Floor, New York, New York 10001, 1-800-294-1322; Deutsche Bank Securities Inc., 100 Plaza One, Floor 2, Jersey City, New Jersey 07311-3901, 1-800-503-4611, prospectusrequest@list.db.com; or J.P. Morgan Securities Inc., Attn: Syndicate Desk, 270 Park Avenue, 8th floor, NY, NY 10017, 212-834-4533.
